<DOC>
	<DOCNO>NCT00729313</DOCNO>
	<brief_summary>The purpose protocol , determine whether lanreotide 30 mg effective treatment patient digestive fistula .</brief_summary>
	<brief_title>Efficacy Safety Lanreotide Versus Placebo Treatment Patients With Digestive Fistulae</brief_title>
	<detailed_description>The purpose study determine whether lanreotide 30mg compare placebo effective evolution drainage volume digestive fistula 72 hour follow begin treatment spontaneous closure time digestive fistula .</detailed_description>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Patient pancreatic , duodenal , small intestine fistula Patient simple , externalise fistula Patient fistula medical conservative treatment consider Patient : pancreatic fistula : mean drainage volume equal 100 ml/24h 48 hour equal 50 ml / 24h 3 day concentration amylase drainage fluid 3 time higher serum least 2 3 consecutive day respectively , duodenal small intestine fistula : mean drainage volume equal 100ml/24h 2 day Patient expect require surgical treatment fistula study Patient uncontrolled intraabdominal sepsis ; Crohn 's disease ; radiotherapy lesion small bowel ; mesenteric vascular insufficiency ; fistula localise cancerinfiltrated area ; distal obstruction ; expose fistula small intestine ; intraabdominal foreign body . Patient receive longterm corticotherapy Patient receive somatostatin analogue curative treatment fistula PRF somatostatin analogue within previous month . Patient previously undergone transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Treatment</keyword>
</DOC>